Find a Faculty

Gold Divider 4Col
Physician Photo

Patient Offices

Address
5 East 98th Street, 11th Floor
New York, NY 10029
Tel
212-241-4060
Office Hours
Monday 9:00 AM - 5:00 PM
Tuesday 9:00 AM - 5:00 PM
Wednesday 9:00 AM - 5:00 PM
Thursday 9:00 AM - 5:00 PM
Friday 9:00 AM - 5:00 PM
Disabled Access
No

Rajeev Rohatgi

ASSISTANT PROFESSOR  Medicine, Nephrology
ASSISTANT PROFESSOR  Pediatrics

Overview

Subspecialty Nephrology
Languages English
Gender Male
E-mail rajeev.rohatgi@mssm.edu
Education and Training MD, New York University
  Residency, Internal Medicine, Mount Sinai Hospital
  Fellowship, Renal Medicine, Mount Sinai Hospital


Curriculum Vitae: http://www.mountsinai.org/supporting-files/cv/roha...

Training

Education and Training MD, New York University
  Residency, Internal Medicine, Mount Sinai Hospital
  Fellowship, Renal Medicine, Mount Sinai Hospital
Board Certification Nephrology

Clinical Practice

Subspecialty Nephrology
Languages English
Board Certification Nephrology

Research

Sodium transport in Autosomal Recessive PKD epithelia

Polycystic kidney disease (PKD) is a common genetic disease that is associated with a high morbidity and mortality. Autosomal dominant PKD (ADPKD) affects ~1:1,000 while autosomal recessive PKD (ARPKD) affects ~1:20,000 live births. Approximately 50 percent of patients with ADPKD develop end-stage renal disease (ESRD) by the sixth decade of life while most infants with ARPKD that survive beyond the perinatal period develop chronic renal failure by early adolescence. In PKD, cyst growth and expansion destroys normal renal parenchyma and leads to renal failure. ADPKD cysts arise from any tubular segment, "bud" off from the nephron, and no longer communicate with the tubule from which they originate. Cysts in ARPKD, however, are actually ectatic dilated collecting ducts which remain contiguous with the filtering nephron, allowing for urine to continue to flow through the dilated collecting system.

Evidence from experimental ADPKD models and human disease suggests that cyst formation and expansion arise, at least in part, from transepithelial solute and fluid secretion. In contrast to the latter observation, we have recently reported that ARPKD cystic collecting ducts, at least early in disease, reabsorb Na. Patch clamp analysis showed that apical Na channel activity in ARPKD cells is ~2 fold greater than that detected in age-matched human fetal collecting tubule (HFCT) cells. The additional observation that steady state expression levels of the and subunits of the apical epithelial Na channel (ENaC), the rate limiting step in Na absorption in the collecting duct, are higher in ARPKD than HFCT cells leads us to hypothesize that ARPKD is associated with upregulated Na absorption, presumably mediated by ENaC. We speculate that dysregulated Na transport contributes to the early onset of hypertension characteristic of this disease. Using assorted molecular (RT-PCR, Northern Blot, Western Blot) and physiologic (patch clamp, Ussing chamber) techniques on a human cell culture model, we plan to elucidate the mechanisms of Na transport in ARPKD renal cystic epithelia.

Publications

Woda CB, Leite Jr M, Rohatgi R, Satlin LM. Effects of luminal flow and nucleotides on [Ca(2+)](i) in rabbit cortical collecting duct. Am J Physiol Renal Physiol 2002 Sep; 283(3): F437-F446.


Rohatgi R, Gharvi A, Satlin LM. There's Gold in Them Ducts. J Pediatr Gastroenterol Nutr 2003 January; 36(1): 154-156.


Delgado MM, Rohatgi R, Khan S, Holzman IR, Satlin LM. Sodium and Potassium Clearances by the maturing kidney: clinical-molecular correlates. Pediatr Nephrol 2003 Aug; 18(8): 759-767.


Rohatgi R, Greenberg C, Burrow C, Wilson P, Satlin LM. Na Transport in Autosomal Recessive Polycystic Kidney Disease (ARPKD) Cyst-lining epithelial cells. J Am Soc Nephrol 2003 April; 14(4): 827-836.


Institutes, Centers, Programs and Laboratories

The Mount Sinai Medical Center is home to an extensive array of top-notch research centers and laboratories, where scientists and researchers work to translate the rapid advances in basic science into the innovative patient care for which we are known.

Clinical Trials

Participating in Mount Sinai’s clinical trials allows you to take advantage of innovative treatments as we work together to advance the future of medicine.

(800) MD-SINAI (800) 637-4624

Visit Mount Sinai Queens